Literature DB >> 6994787

Effect of guanfacine on blood pressure and renin activity in hypertensive patients.

J Rosenthal.   

Abstract

1. The effect of treatment with guanfacine for 12 weeks on blood pressure and plasma renin activity was investigated in 24 hypertensive patients (WHO I-III). 2. Systolic, diastolic and mean blood pressure values underwent significant reductions with a constant dose of guanfacine 3 mg daily for 1 week: from 197/115/149 (systolic/diastolic/mean) mmHg before therapy to 166/97/126 mmHg. After 4 weeks of treatment at varying doses, the blood pressure decreased to 157/91/118 mmHg, and after 12 weeks of treatment it levelled off at 147/83/109 mmHg. Heart rate remained essentially unchanged throughout the observation period. 3. During exercise, blood pressure and heart rate increased to the same extent during therapy as before treatment. Orthostatic hypotension was not seen in any of the patients. 4. Renin values decreased under therapy from 3.3 to 2.3 ng ml-1 h-1, but at no time during treatment did this decrease correlate with that of blood pressure. 5. Guanfacine treatment was accompanied by relatively few and mild side-effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994787      PMCID: PMC1430117          DOI: 10.1111/j.1365-2125.1980.tb04913.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  [Standardization of orthostatic stress. Comparison of orthostatic stress under laboratory and routine conditions].

Authors:  H Jarmatz; H de Marées; G Kunitsch
Journal:  Med Welt       Date:  1976-09-17

2.  Effects of clonidine and BS 100-141 on the EEG sleep pattern in rats.

Authors:  H Kleinlogel; G Scholtysik; A C Sayers
Journal:  Eur J Pharmacol       Date:  1975-08       Impact factor: 4.432

3.  Pharmacology of BS 100-141, a centrally acting antihypertensive drug.

Authors:  K Saameli; G Scholtysik; R Waite
Journal:  Clin Exp Pharmacol Physiol       Date:  1975       Impact factor: 2.557

4.  A new centrally action antihypertensive agent guanfacine (BS 100-141).

Authors:  U C Dubach; R Huwyler; P Radielovic; M Singeisen
Journal:  Arzneimittelforschung       Date:  1977

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  Hemodynamic changes at rest and during exercise in long-term clonidine therapy of essential hypertension.

Authors:  P Lund-Johansen
Journal:  Acta Med Scand       Date:  1974 Jan-Feb

7.  Plasma renin activity, blood pressure and sodium excretion during treatment with clonidine.

Authors:  F Fyhrquist; K Kurppa; M Huuskonen
Journal:  Acta Med Scand       Date:  1975-06

8.  Clonidine in primary hypertension: effects on blood pressure, plasma renin activity, plasma and urinary aldosterone.

Authors:  B E Karlberg; O Nilsson; K Tolagen
Journal:  Curr Ther Res Clin Exp       Date:  1977-01

9.  Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).

Authors:  G Scholtysik; H Lauener; E Eichenberger; H Bürki; R Salzmann; E Müller-Schweinitzer; R Waite
Journal:  Arzneimittelforschung       Date:  1975-10

10.  Renin and aldosterone suppression in the antihypertensive action of clonidine.

Authors:  M A Weber; D B Case; L Baer; J E Sealey; J I Drayer; J A Lopez-Overjero; J H Laragh
Journal:  Am J Cardiol       Date:  1976-11-23       Impact factor: 2.778

View more
  1 in total

Review 1.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.